The Technical AnalystExchange: NSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Neuland Laboratories Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.36% INR7 457.65
America/New_York / 8 mai 2024 @ 05:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 95 681 mill |
| EPS: | 247.22 |
| P/E: | 30.17 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 12.83 mill |
| Avg Daily Volume: | 0.0457 mill |
| RATING 2024-05-08 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 30.17 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 30.17 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
INR1 309.42 (-82.44%) INR-6 148.23 |
| Date: 2024-05-08 |
| Expected Trading Range (DAY) |
|---|
|
INR 7 121.86 - 7 793.44 ( +/- 4.50%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | INR7 457.65 (1.36% ) |
| Volume | 0.0104 mill |
| Avg. Vol. | 0.0457 mill |
| % of Avg. Vol | 22.87 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NEULANDLAB.NS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NEULANDLAB.NS
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.